Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results
CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery...
United Kingdom Pointe Claire Bruce Pritchard Nicole Rusaw Antagonist Development Plan Agonist Development Plan
Source: prnewswire.com